Delving into the Latest Updates on Silibinin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Silibinin (INN), Silibinin A, Silybin A

+ [12]

Target-

Mechanism-

Therapeutic Areas

Digestive System Disorders

Active Indication

Liver Diseases

Inactive Indication

liver function failureNonalcoholic Steatohepatitis

Originator Organization-

Active Organization-

Inactive Organization

Madaus SANhat Nhat Pharmaceutical Co.，Ltd

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure

Molecular FormulaC25H22O10

InChIKeySEBFKMXJBCUCAI-HKTJVKLFSA-N

CAS Registry22888-70-6

BACKGROUNDThis study aimed to assess silymarin's anticancer and antifibrotic potential through in silico analysis and investigate its impact on in vitro arecoline-induced fibrosis in primary human buccal fibroblasts (HBF).METHODS & RESULTSThe study utilized iGEMDOCK for molecular docking, evaluating nine bioflavonoids, and identified silymarin and baicalein as the top two compounds with the highest target affinity, followed by subsequent validation through a 100ns Molecular Dynamic Simulation demonstrating silymarin's stable behavior with Transforming Growth Factor Beta. HBF cell lines were developed from tissue samples obtained from patients undergoing third molar extraction. Arecoline, a known etiological factor in oral submucous fibrosis (OSMF), was employed to induce fibrogenesis in these HBFs. The inhibitory concentration (IC₅₀) of arecoline was determined using the MTT assay, revealing dose-dependent cytotoxicity of HBFs to arecoline, with notable cytotoxicity observed at concentrations exceeding 50µM. Subsequently, the cytotoxicity of silymarin was assessed at 24 and 72 h, spanning concentrations from 5µM to 200µM, and an IC₅₀ value of 143µM was determined. Real-time polymerase chain reaction (qPCR) was used to analyze the significant downregulation of key markers including collagen, epithelial-mesenchymal transition (EMT), stem cell, hypoxia, angiogenesis and stress markers in silymarin-treated arecoline-induced primary buccal fibroblast cells.CONCLUSIONSilymarin effectively inhibited fibroblast proliferation and downregulated genes associated with cancer progression and EMT pathway, both of which are implicated in malignant transformation. To our knowledge, this study represents the first exploration of silymarin's potential as a novel therapeutic agent in an in vitro model of OSMF.

01 Dec 2024·Molecular Biology Reports

Co-treatment of silymarin and cisplatin inhibited cell proliferation, induced apoptosis in ovarian cancer

Article

Author: Reiisi, Somayeh ; Masoudi Chelegahi, Afsane ; Karimzadeh, Mohammad Reza ; Shahbazi, Shahrzad

BACKGROUNDOvarian cancer is one of the most lethal gynecological cancers among women worldwide. Cisplatin (Cis) is an effective chemotherapeutic agent used to treat several types of cancer. Silymarin (SLM) is an extract of medicinal plant Silybum marianum (milk thistle) with anti-inflammatory, anti-angiogenesis, antioxidant, and anticancer properties used alone or in combination with other drugs.OBJECTIVEThis study aimed to explore the effects of co-treatment with SLM and Cis on A2780 human ovarian cancer cell lines.METHODSIn this study, A2780 cells were treated with various concentrations of SLM and Cis, separately and in combination. Cell cytotoxicity, scratch, clonogenic, and flow-cytometry assays were accomplished to estimate cell viability, migration, colony formation, and apoptosis, respectively. Real-time PCR was utilized to determine the expression levels of miR-155 and miR-27a.RESULTSSLM significantly reduced the proliferation of A2780 cells in a concentration- and time-dependent manner. Combination treatment with SLM and Cis was more potent than either single treatment in reducing viability, suppressing migration, inhibiting colony formation, and promoting the induction of apoptosis. Additionally, gene expression analysis revealed a significant decline in the expression levels of miR-155 and miR-27a in response to all separate and combined treatments, and co-treatment was more effective than individual treatments in altering miRNAs expression.CONCLUSIONBased on our findings, SLM boosts the anticancer activity of Cis and mitigates its side effects. Thus, the co-treatment of SLM and Cis can be proposed as a promising therapeutic strategy for further investigation.

01 Dec 2024·Molecular Biology Reports

Silymarin and MSC-exosomes ameliorate thioacetamide-evoked renal fibrosis by inhibiting TGF-β/SMAD pathway in rats

Article

Author: Mekawy, Dina Mohamed ; Sabry, Rania Mohamed ; Abozeid, Naglaa F ; Sabry, Dina

AbstractBackgroundTGF-β1 and SMAD3 are particularly pathogenic in the progression of renal fibrosis.AimThis study aimed to evaluate the kidney protective potentials of silymarin (SM) and exosomes of mesenchymal stem cells against the nephrotoxin thioacetamide (TAA) in rats.Methods32 female rats were randomly assigned into four groups: the control group, the TAA group, the TAA + SM group, and the TAA + Exosomes group. The kidney homogenates from all groups were examined for expression levels of TGF-β receptors I and II using real-time PCR, expression levels of collagen type I and CTGF proteins using ELISA, and the expression levels of nuclear SMAD2/3/4, cytoplasmic SMAD2/3, and cytoplasmic SMAD4 proteins using the western blot technique.ResultsCompared to the control group, the injection of TAA resulted in a significant increase in serum levels of urea and creatinine, gene expression levels of TβRI and TβRII, protein expression levels of both collagen I and CTGF proteins, cytoplasmic SMAD2/3 complex, and nuclear SMAD2/3/4 (p-value < 0.0001), with significantly decreased levels of the co-SMAD partner, SMAD4 (p-value < 0.0001). Those effects were reversed considerably in both treatment groups, with the superiority of the exosomal treatment regarding the SMAD proteins and the expression levels of the TβRI gene, collagen I, and CTGF proteins returning to near-control values (p-value > 0.05).ConclusionUsing in vitro and in vivo experimental approaches, the research discovered a reno-protective role of silymarin and exosomes of BM-MSCs after thioacetamide-induced renal fibrosis in rats, with the advantage of exosomes.

1

News (Medical) associated with Silibinin

16 Feb 2024

·www.prnewswire.com

Capsulyte Unveils PREGAME: The Ultimate Solution for Party Recovery, Marking Its Debut at DC Fashion Week

Capsulyte PREGAME, a doctor formulated supplement to aid alcohol recovery, launches at DC Fashion Week as the hangover recovery market is set to grow over the next decade. CRANBURY, N.J., Feb. 16, 2024 /PRNewswire/ -- Capitalizing on cutting-edge ingredients, Capsulyte's PREGAME has emerged as the most advanced product to aid in party recovery and address symptoms often associated with hangovers. As a significant milestone for the brand, Capsulyte has been invited to participate in the prestigious DC Fashion Week, a testament to the company's alignment with premium lifestyles and the fashion industry's elite. This invitation further underscores Capsulyte's commitment to excellence and positions PREGAME as the preferred choice for discerning individuals seeking to enjoy social occasions to the fullest, without the next-day regrets. Many individuals face the unpleasant reality of hangover symptoms such as headaches, fatigue, and nausea, resulting from alcohol consumption. These effects can be primarily attributed to acetaldehyde, a toxic compound that is created when the liver metabolizes alcohol. According to Persistence Market Research, the global hangover recovery market is estimated to reach $4.2 billion by the year 2030. PREGAME is uniquely situated to help solve the issue of acetaldehyde accumulation among individuals who want to live healthy, balanced lives while also maintaining their productivity. PREGAME addresses the challenge of party recovery head-on with a formulation enriched with the scientifically backed ingredients Siliphos® and Clovinol® to support liver detoxification, overall liver health, and acetaldehyde metabolism. Siliphos®, a patented botanical derivative from milk thistle, has been clinically shown to improve liver function, inhibit fibrotic cells, and shield against oxidative stress. Its unique Phytosome technology enhances the bioavailability of silybin, a key component for liver health that is otherwise poorly absorbed by the body. This innovative approach ensures marked improvement over standard milk thistle extracts, offering comprehensive liver protection and recovery. Clovinol®, sourced from the potent spice clove, is distinguished by its capacity to increase the potent antioxidant, glutathione. It's also a robust liver protector that accelerates the elimination of acetaldehyde from the body up to 2.5 times faster than usual, thereby reducing alcohol's negative effects and the severity of symptoms associated with hangovers. With the synergy of Siliphos® and Clovinol®, combined with Dihydromyricetin (DHM) and N-Acetyl Cysteine (NAC), PREGAME represents the pinnacle of a doctor-formulated, research-backed solution for those seeking to mitigate the aftereffects of alcohol consumption. As the brand marks its presence at DC Fashion Week, Capsulyte is set to redefine the standards of social indulgence and wellness. Its participation not only highlights the efficacy and luxury associated with PREGAME but also solidifies Capsulyte's stance as a trailblazer in the dietary supplement industry. Unlock the ability to embrace a healthier, more vibrant lifestyle with Capsulyte's PREGAME, where premium care meets unparalleled social experiences. Capsulyte's PREGAME and HYDRATION are available on the store site and Amazon. FDA Disclaimer: The statements made regarding this product have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from healthcare practitioners. Please consult your doctor. The news site hosting this press release is not associated with Capsulyte. It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service. About Capsulyte Capsulyte is a doctor-founded dietary supplement company dedicated to enhancing the health and wellbeing of individuals through scientifically backed, innovative products. Specializing in alcohol and party recovery solutions, Capsulyte is committed to delivering superior quality, efficacy, and safety in every product, supporting people in living their best lives. For more information, visit Press Contact Dan Nguyen 908-292-3110 SOURCE Capsulyte

100 Deals associated with Silibinin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08515	Silibinin	A05BA03	DB09298

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Liver Diseases	-	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonalcoholic Steatohepatitis	Phase 2	US	Madaus SA	01 Apr 2008
liver function failure	Phase 1	VN	Nhat Nhat Pharmaceutical Co.，Ltd	15 Jun 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00680407 (Pubmed)	Phase 2	Nonalcoholic Steatohepatitis	78	Legalon® 420 mg	sovyfpvfyc(owofykmdwb) = wsmirxekrf oybisanxap (obxrzkiiml )	-	01 Jan 2019
				Legalon® 700 mg	sovyfpvfyc(owofykmdwb) = kcdspgupgu oybisanxap (obxrzkiiml )
NCT01816490 (Pubmed \| J Biol Chem)	Phase 2	HIV Infections \| Hepatitis C	16	Silibinin lead-in therapy	dezhhhrfxl(djeipncvga) = ngxxucdfcl uylpwfkspn (vsnklpsdcu, 2.1 - 2.8)	Positive	01 Jan 2015
ACTRN12619001296123 (Pubmed)	Not Applicable	Multiple Endocrine Neoplasia	17	Silymarin	oxxlenfswj(rvrcmyibks) = vtkjjbhiyi nszlxhhqyi (muxjjxkzlo ) View more	-	09 Jul 2021
				Placebo	oxxlenfswj(rvrcmyibks) = bfbzyghzmr nszlxhhqyi (muxjjxkzlo ) View more
Pubmed \| Chin J Integr Med	Not Applicable	Colitis, Ulcerative	80	Silymarin	(uuoiejwsba) = cefqdytcpr nkuuxkhsjp (njsdmgigap ) View more	Positive	01 Dec 2015
				Placebo	(uuoiejwsba) = rxoygapbut nkuuxkhsjp (njsdmgigap ) View more
NCT00680342 (Pubmed \| J Coll Physicians Surg Pak)	Phase 2	Hepatitis C, Chronic	154	420-mg silymarin	(crhprzvsut) = pxaoxpaiho ycvbaiexvc (tzkdyagwzw )	Negative	18 Jul 2012
				700-mg silymarin	(crhprzvsut) = tpyuobtpri ycvbaiexvc (tzkdyagwzw )
NCT02006498 (Pubmed \| Clin Gastroenterol Hepatol) Manual	Phase 2	Nonalcoholic Steatohepatitis	99	Silymarin	(khbasjepec) = vwakypxfop uaikfbyxoj (riyvgdiknu ) View more	Positive	01 Dec 2017
				Placebo	(khbasjepec) = ptjuyzwcjj uaikfbyxoj (riyvgdiknu ) View more
IAS2014	Not Applicable	HIV Infections \| Hepatitis C	17	Silibinin lead-in + triple therapy	rxknmvzmrz(pevpssabrm) = hsqidgkmgb tfapjjjuav (xtyrjaqeyx ) View more	-	01 Jan 2014
SUSTAIN (ASCO2023) Manual	Phase 2	Brain metastases	30	silibinin	(ackrsvdwhz) = Two pts discontinued silibinin-based nutraceutical assumption due to G1 nausea. No other adverse events were reported. qrylnijhqc (qeamolatce )	Positive	31 May 2023
EULAR2009	Not Applicable	Osteoarthritis, Knee interleukin-1alpha \| interleukin-8 \| complement proteins C3	220	Piroxicam 20mg/day	(njwtlgjxep) = yughbrbmkz valdyejgux (dancvggnwl ) View more	Positive	10 Jun 2009
				Silymarin + Piroxicam	(njwtlgjxep) = qrycvaoaby valdyejgux (dancvggnwl ) View more
AACR2013	Not Applicable	Basal Cell Carcinoma	-	Silibinin	zdvfxmdpfd(vfkolzqtrs) = smanxpgdcm xrcgecshmh (mfbyziyfsc ) View more	-	15 Apr 2013
				DMSO	zdvfxmdpfd(vfkolzqtrs) = pbbjfzywpi xrcgecshmh (mfbyziyfsc ) View more